Wednesday, August 27th, 2025
Stock Profile: CORT
CORT Logo

Corcept Therapeutics Incorporated (CORT)

Market: NASD | Currency: USD

Address: 149 Commonwealth Drive

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for Show more




📈 Corcept Therapeutics Incorporated Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for Corcept Therapeutics Incorporated


DateReported EPS
2025-10-29 (estimated upcoming)-
2025-07-310.29
2025-05-050.17
2025-02-260.26
2024-10-300.41
2024-07-290.32
2024-05-010.25
2024-02-150.28
2023-11-010.28
2023-08-020.25
2023-05-030.14
2023-02-280.14
2022-11-030.3
2022-08-030.24
2022-05-050.2
2022-02-150.35
2021-11-030.24
2021-07-290.3
2021-05-060.2
2021-02-230.27
2020-11-030.24
2020-08-040.32
2020-05-040.34
2020-02-200.33
2019-11-070.31




📰 Related News & Research


No related articles found for "corcept therapeutics".